Conecte-se

Bibliografias temáticas / Lymphocytes T régulateurs – Cancer / Livros

Siga este link para ver outros tipos de publicações sobre o tema: Lymphocytes T régulateurs – Cancer.

Livros sobre o tema "Lymphocytes T régulateurs – Cancer"

Autor: Grafiati

Publicado: 1 de fevereiro de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 19 melhores livros para estudos sobre o assunto "Lymphocytes T régulateurs – Cancer".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os livros das mais diversas áreas científicas e compile uma bibliografia correta.

1

L, Kripke Margaret, Frost Philip 1940- e M.D. Anderson Hospital and Tumor Institute., eds. Immunology and cancer. Austin: Published for the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Tex. by the University of Texas Press, 1986.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Alexander, Michael A. Immune-based cancer treatment: The T lymphocyte response. Boca Raton, FL: CRC Press, 2011.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Alexander, Michael A. Immune-based cancer treatment: The T lymphocyte response. Boca Raton, FL: CRC Press, 2011.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Clark, Lambert W., Giannotti B, Vloten W. A. van, North Atlantic Treaty Organization. Scientific Affairs Division. e NATO Advanced Research Workshop on Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin (1991 : San Miniato, Italy), eds. Basic mechanisms of physiologic and aberrant lymphoproliferation in the skin. New York: Plenum Press, 1994.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Symposium, Takamatsu no Miya Hi Gan Kenkyū Kikin International. Retroviruses in human lymphoma/leukemia: Proceedings of the 15th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1984. Tokyo: Japan Scientific Societies Press, 1985.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

1944-, Finke James H., e Bukowski Ronald M, eds. Cancer immunotherapy at the crossroads: How tumors evade immunity and what can be done. Totowa, N.J: Humana Press, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

1944-, Finke James H., e Bukowski Ronald M, eds. Cancer immunotherapy at the crossroads: How tumors evade immunity and what can be done. Totowa, N.J: Humana Press, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Burkhard, Ludewig, e Hoffmann Matthias W, eds. Adoptive immunotherapy: Methods and protocols. Totowa, N.J: Humana Press, 2005.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Immunotherapy of cancer with sensitized T lymphocytes. Austin: R.G. Landes, 1994.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Medin, Jeffrey, e Daniel Fowler. Experimental and Applied Immunotherapy. Springer, 2011.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Medin, Jeffrey, e Daniel Fowler. Experimental and Applied Immunotherapy. Humana, 2014.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Cellular Therapy Of Cancer. World Scientific Publishing Company, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

(Editor), James H. Finke, e Ronald M. Bukowski (Editor), eds. Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology). Humana Press, 2003.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

McMichael, A. J. A New Look at Tumour Immunology (Cancer Surveys Series Vol 13) (Cancer Surveys Series Vol 13). Cold Spring Harbor Laboratory Pr, 1992.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

(Editor), K. Kikuchi, B. J. Van Den Eynde (Editor) e N. Sato (Editor), eds. Recent Advances of Human Tumor Immunology and Immunotherapy (Gann Monograph on Cancer Research). Not Avail, 1999.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Hawkins, Robert E. Cellular Therapy of Cancer: Development of Gene Therapy Based Approaches. World Scientific Publishing Co Pte Ltd, 2014.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Ludewig, Burkhard, e Matthias W. Hoffmann. Adoptive Immunotherapy: Methods and Protocols. Humana Press, 2010.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Adoptive immunotherapy: Methods and protocols. Totowa, NJ: Humana Press, 2004.

Encontre o texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Moerdler, Scott, e Xingxing Zang. PD-1/PDL-1 Inhibitors as Immunotherapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0010.

Texto completo da fonte

Resumo:

Programmed death 1 (PD-1), a member of the B7-CD28 immunoglobulin superfamily, and its ligands PD-L1/PD-L2 inhibit T-cell activation. They also play a key role in the tumor microenvironment, allowing for cancer immune escape. PD-1 is induced on a variety of immune cells, including tumor-infiltrating lymphocytes (TILs), while PD-L1 is found on many types of solid tumors including ovarian cancer and some TILs. The use of immunocheckpoint inhibitors like anti-PD-1 and anti-PD-L1 therapies has been shown to reactivate the immune system to attack tumor cells. Ovarian cancers have been shown to be responsive to anti-PD-1 and anti-PD-L1 therapies, though immunocheckpoint inhibitors are not enough. Current research is evaluating combination therapies to improve response rates.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!